Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ+/CD19+ Depleted Haploidentical HSCT and Zoledronate for Pediatric Relapsed/Refractory Malignancies
NCT02508038Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2016
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zoledronate in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL) and 8 more, sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of acute graft versus host disease (GVHD) at 100 days and Incidence of graft failure at 28 days. Started Feb 2016; status: recruiting.
02
Drugs
zoledronate
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02508038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508038.